X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
TVB-2640 (denifanstat) is an orally bioavailable fatty acid synthase (FASN) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of Nonalcoholic Fatty Liver Disease.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
TVB-2640 (denifanstat) is an oral, selective FASN inhibitor which is under phase 2 clinical development for the treatment of non-alcoholic steatohepatitis patients with stage 2 or stage 3 fibrosis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.
Lead Product(s): Denifanstat
Therapeutic Area: Dermatology Product Name: ASC40
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in combined with bevacizumab for the treatment of recurrent glioblastoma.
Lead Product(s): Denifanstat,Bevacizumab
Therapeutic Area: Oncology Product Name: ASC40
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ascletis Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated for the treatment of mild-moderate acne vulgaris.
Lead Product(s): Denifanstat
Therapeutic Area: Dermatology Product Name: ASC40
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN), a key enzyme which regulates DNL. Human sebum production requires de novo lipogenesis, which is increased in acne and can be suppressed by the FASN inhibitor ASC40.
Lead Product(s): Denifanstat
Therapeutic Area: Dermatology Product Name: ASC40
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Denifanstat (TVB-2640) is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
An analysis of the full patient population at 52 weeks will evaluate the impact of TVB-2640 (denifanstat) treatment or placebo as assessed by biopsy, with primary efficacy endpoints that include improvement in NASH activity score or improvement in fibrosis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Denifanstat (TVB-2640), the company’s lead product candidate, is an oral, selective, first-in-class fatty acid synthase inhibitor. Denifanstat’s unique mechanism of action directly targets the primary drivers of NASH by reducing excess liver fat.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Denifanstat (formerly known as TVB-2640) is a wholly owned, oral, selective inhibitor of FASN, a key enzyme involved in the production of saturated fatty acids in the liver and other organs.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
TVB-2640 (denifanstat) is a wholly owned, oral, selective inhibitor of FASN, a key enzyme involved in the production of saturated fatty acids in the liver and other organs.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TVB-2640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
